High SOX2 Expression is Associated with Poor Survival in Patients with Newly Diagnosed Multiple Myeloma

Overview

Journal Blood Cancer J

Date 2023 May 22

PMID 37217520

Authors

Xinhe Shan

Qi Long

Alfred L Garfall

Sandra P Susanibar-Adaniya

Affiliations

Soon will be listed here.

References

Tanno T, Lim Y, Wang Q, Chesi M, Bergsagel P, Matthews G . Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells. Blood. 2013; 123(5):725-33. PMC: 3907757. DOI: 10.1182/blood-2013-08-524025. View

He H, Li Z, Lu J, Qiang W, Jiang S, Xu Y . Single-cell RNA-seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma. Clin Transl Med. 2022; 12(3):e757. PMC: 8926895. DOI: 10.1002/ctm2.757. View

Gan L, Xu M, Hua R, Tan C, Zhang J, Gong Y . The polycomb group protein EZH2 induces epithelial-mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter. J Hematol Oncol. 2018; 11(1):9. PMC: 5769437. DOI: 10.1186/s13045-017-0547-3. View

Goldsmith S, Fiala M, ONeal J, Souroullas G, Toama W, Vij R . EZH2 Overexpression in Multiple Myeloma: Prognostic Value, Correlation With Clinical Characteristics, and Possible Mechanisms. Clin Lymphoma Myeloma Leuk. 2019; 19(11):744-750. DOI: 10.1016/j.clml.2019.08.010. View

Shiba K, Kawahara T . Using Propensity Scores for Causal Inference: Pitfalls and Tips. J Epidemiol. 2021; 31(8):457-463. PMC: 8275441. DOI: 10.2188/jea.JE20210145. View

Mu P, Zhang Z, Benelli M, Karthaus W, Hoover E, Chen C . SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer. Science. 2017; 355(6320):84-88. PMC: 5247742. DOI: 10.1126/science.aah4307. View

Dhodapkar M, Sexton R, Das R, Dhodapkar K, Zhang L, Sundaram R . Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy. Blood. 2015; 126(22):2475-8. PMC: 4661169. DOI: 10.1182/blood-2015-03-632919. View

Dhodapkar K, Cohen A, Kaushal A, Garfall A, Manalo R, Carr A . Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma. Blood Cancer Discov. 2022; 3(6):490-501. PMC: 9627239. DOI: 10.1158/2643-3230.BCD-22-0018. View

Garfall A, Stadtmauer E, Hwang W, Lacey S, Melenhorst J, Krevvata M . Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight. 2018; 3(8). PMC: 5931130. DOI: 10.1172/jci.insight.120505. View

10.

Tianhua Y, Dianqiu L, Xuanhe Z, Zhe Z, Dongmei G . Long non-coding RNA Sox2 overlapping transcript (SOX2OT) promotes multiple myeloma progression via microRNA-143-3p/c-MET axis. J Cell Mol Med. 2020; 24(9):5185-5194. PMC: 7205799. DOI: 10.1111/jcmm.15171. View

11.

Kalaszczynska I, Geng Y, Iino T, Mizuno S, Choi Y, Kondratiuk I . Cyclin A is redundant in fibroblasts but essential in hematopoietic and embryonic stem cells. Cell. 2009; 138(2):352-65. PMC: 2745999. DOI: 10.1016/j.cell.2009.04.062. View

12.

Verma R, Branagan A, Xu M, Flavell R, Dhodapkar K, Dhodapkar M . Role of MBD3-SOX2 axis in residual myeloma following pomalidomide. Leukemia. 2021; 35(11):3319-3323. PMC: 8371090. DOI: 10.1038/s41375-021-01145-0. View

13.

Garfall A, Cohen A, Susanibar-Adaniya S, Hwang W, Vogl D, Waxman A . Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy. Blood Cancer Discov. 2022; 4(2):118-133. PMC: 9975770. DOI: 10.1158/2643-3230.BCD-22-0074. View